Company Profile
Mustang Bio Stock Price, News & Analysis
Company overview
Business overview
Mustang Bio is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Mustang Bio is followed within the biotech universe for its exposure to catalyst-driven execution.
Business Model Characteristics
Mustang Bio follows a catalyst-driven model where the market watches how the company turns development work into repeatable value creation.
Position Within the Biotechnology Landscape
Compared with more mature healthcare peers, Mustang Bio sits closer to the development side of the biotechnology landscape, where timing around data and approvals matters most.
Why the stock is moving
MBIO is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
Mustang Bio’s catalysts are its cell-therapy pipeline, especially any update that clarifies whether the CAR-T and gene-therapy assets still have enough momentum. The stock remains highly data-sensitive.
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
Mustang Bio Announces Exercise of Warrants for $4 Million Gross Proceeds
Source: Mustang Bio
- 02
- 03
Mustang Bio Receives Positive Listing Determination from Nasdaq
Source: Mustang Bio
- 04
Mustang Bio Announces Reverse Stock Split
Source: Mustang Bio
- 05
Mustang Bio Announces Pricing of $8 Million Public Offering
Source: Mustang Bio
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.